Moderate to Persistent Asthma in the Obese Subject

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
Obesity is associated with increased airway inflammation and asthma severity that results in suboptimal control of asthma despite therapy with high dose inhaled corticosteroids (ICS). The investigators suggested that the addition of Singular (montelukast)\[LTRA\] to moderate doses of inhaled corticosteroids will improve asthma control. This cross over study will be treat subjects with moderate dose ICS/LTRA for 12 weeks and high dose ICS with placebo for 12 weeks.
Epistemonikos ID: b54aa82c71885be5468075af1f169b428fb2b9bf
First added on: May 05, 2024